Construction and next-generation sequencing analysis of a large phage-displayed VNAR single-domain antibody library from six naïve nurse sharks.
Identifieur interne : 000627 ( PubMed/Checkpoint ); précédent : 000626; suivant : 000628Construction and next-generation sequencing analysis of a large phage-displayed VNAR single-domain antibody library from six naïve nurse sharks.
Auteurs : Mingqian Feng [États-Unis] ; Hejiao Bian [États-Unis] ; Xiaolin Wu [États-Unis] ; Tianyun Fu [États-Unis] ; Ying Fu [États-Unis] ; Jessica Hong [États-Unis] ; Bryan D. Fleming [États-Unis] ; Martin F. Flajnik [États-Unis] ; Mitchell Ho [États-Unis]Source :
- Antibody therapeutics [ 2516-4236 ] ; 2019.
Abstract
Background: Shark new antigen receptor variable domain (VNAR) antibodies can bind restricted epitopes that may be inaccessible to conventional antibodies. Methods: Here, we developed a library construction method based on polymerase chain reaction (PCR)-Extension Assembly and Self-Ligation (named "EASeL") to construct a large VNAR antibody library with a size of 1.2 × 1010 from six naïve adult nurse sharks (Ginglymostoma cirratum). Results: The next-generation sequencing analysis of 1.19 million full-length VNARs revealed that this library is highly diversified because it covers all four classical VNAR types (Types I-IV) including 11% of classical Type I and 57% of classical Type II. About 30% of the total VNARs could not be categorized as any of the classical types. The high variability of complementarity determining region (CDR) 3 length and cysteine numbers are important for the diversity of VNARs. To validate the use of the shark VNAR library for antibody discovery, we isolated a panel of VNAR phage binders to cancer therapy-related antigens, including glypican-3, human epidermal growth factor receptor 2 (HER2), and programmed cell death-1 (PD1). Additionally, we identified binders to viral antigens that included the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) spike proteins. The isolated shark single-domain antibodies including Type I and Type II VNARs were produced in Escherichia coli and validated for their antigen binding. A Type II VNAR (PE38-B6) has a high affinity (Kd = 10.1 nM) for its antigen. Conclusions: The naïve nurse shark VNAR library is a useful source for isolating single-domain antibodies to a wide range of antigens. The EASeL method may be applicable to the construction of other large diversity gene expression libraries.
DOI: 10.1093/abt/tby011
PubMed: 30627698
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:30627698Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Construction and next-generation sequencing analysis of a large phage-displayed V<sub>NAR</sub> single-domain antibody library from six naïve nurse sharks.</title><author><name sortKey="Feng, Mingqian" sort="Feng, Mingqian" uniqKey="Feng M" first="Mingqian" last="Feng">Mingqian Feng</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bian, Hejiao" sort="Bian, Hejiao" uniqKey="Bian H" first="Hejiao" last="Bian">Hejiao Bian</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Wu, Xiaolin" sort="Wu, Xiaolin" uniqKey="Wu X" first="Xiaolin" last="Wu">Xiaolin Wu</name><affiliation wicri:level="2"><nlm:affiliation>Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Fu, Tianyun" sort="Fu, Tianyun" uniqKey="Fu T" first="Tianyun" last="Fu">Tianyun Fu</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Fu, Ying" sort="Fu, Ying" uniqKey="Fu Y" first="Ying" last="Fu">Ying Fu</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Hong, Jessica" sort="Hong, Jessica" uniqKey="Hong J" first="Jessica" last="Hong">Jessica Hong</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Fleming, Bryan D" sort="Fleming, Bryan D" uniqKey="Fleming B" first="Bryan D" last="Fleming">Bryan D. Fleming</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Flajnik, Martin F" sort="Flajnik, Martin F" uniqKey="Flajnik M" first="Martin F" last="Flajnik">Martin F. Flajnik</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland Baltimore School of Medicine, Baltimore, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, University of Maryland Baltimore School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ho, Mitchell" sort="Ho, Mitchell" uniqKey="Ho M" first="Mitchell" last="Ho">Mitchell Ho</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30627698</idno><idno type="pmid">30627698</idno><idno type="doi">10.1093/abt/tby011</idno><idno type="wicri:Area/PubMed/Corpus">000680</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000680</idno><idno type="wicri:Area/PubMed/Curation">000680</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000680</idno><idno type="wicri:Area/PubMed/Checkpoint">000627</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000627</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Construction and next-generation sequencing analysis of a large phage-displayed V<sub>NAR</sub> single-domain antibody library from six naïve nurse sharks.</title><author><name sortKey="Feng, Mingqian" sort="Feng, Mingqian" uniqKey="Feng M" first="Mingqian" last="Feng">Mingqian Feng</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bian, Hejiao" sort="Bian, Hejiao" uniqKey="Bian H" first="Hejiao" last="Bian">Hejiao Bian</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Wu, Xiaolin" sort="Wu, Xiaolin" uniqKey="Wu X" first="Xiaolin" last="Wu">Xiaolin Wu</name><affiliation wicri:level="2"><nlm:affiliation>Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Fu, Tianyun" sort="Fu, Tianyun" uniqKey="Fu T" first="Tianyun" last="Fu">Tianyun Fu</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Fu, Ying" sort="Fu, Ying" uniqKey="Fu Y" first="Ying" last="Fu">Ying Fu</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Hong, Jessica" sort="Hong, Jessica" uniqKey="Hong J" first="Jessica" last="Hong">Jessica Hong</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Fleming, Bryan D" sort="Fleming, Bryan D" uniqKey="Fleming B" first="Bryan D" last="Fleming">Bryan D. Fleming</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Flajnik, Martin F" sort="Flajnik, Martin F" uniqKey="Flajnik M" first="Martin F" last="Flajnik">Martin F. Flajnik</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland Baltimore School of Medicine, Baltimore, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, University of Maryland Baltimore School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ho, Mitchell" sort="Ho, Mitchell" uniqKey="Ho M" first="Mitchell" last="Ho">Mitchell Ho</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j">Antibody therapeutics</title><idno type="eISSN">2516-4236</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Background:</b> Shark new antigen receptor variable domain (V<sub>NAR</sub>) antibodies can bind restricted epitopes that may be inaccessible to conventional antibodies. <b>Methods:</b> Here, we developed a library construction method based on polymerase chain reaction (PCR)-Extension Assembly and Self-Ligation (named "EASeL") to construct a large V<sub>NAR</sub> antibody library with a size of 1.2 × 10<sup>10</sup> from six naïve adult nurse sharks (<i>Ginglymostoma cirratum</i>). <b>Results:</b> The next-generation sequencing analysis of 1.19 million full-length V<sub>NAR</sub>s revealed that this library is highly diversified because it covers all four classical V<sub>NAR</sub> types (Types I-IV) including 11% of classical Type I and 57% of classical Type II. About 30% of the total V<sub>NAR</sub>s could not be categorized as any of the classical types. The high variability of complementarity determining region (CDR) 3 length and cysteine numbers are important for the diversity of V<sub>NAR</sub>s. To validate the use of the shark V<sub>NAR</sub> library for antibody discovery, we isolated a panel of V<sub>NAR</sub> phage binders to cancer therapy-related antigens, including glypican-3, human epidermal growth factor receptor 2 (HER2), and programmed cell death-1 (PD1). Additionally, we identified binders to viral antigens that included the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) spike proteins. The isolated shark single-domain antibodies including Type I and Type II V<sub>NAR</sub>s were produced in <i>Escherichia coli</i> and validated for their antigen binding. A Type II V<sub>NAR</sub> (PE38-B6) has a high affinity (K<sub>d</sub> = 10.1 nM) for its antigen. <b>Conclusions:</b> The naïve nurse shark V<sub>NAR</sub> library is a useful source for isolating single-domain antibodies to a wide range of antigens. The EASeL method may be applicable to the construction of other large diversity gene expression libraries.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30627698</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2516-4236</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Antibody therapeutics</Title><ISOAbbreviation>Antib Ther</ISOAbbreviation></Journal><ArticleTitle>Construction and next-generation sequencing analysis of a large phage-displayed V<sub>NAR</sub> single-domain antibody library from six naïve nurse sharks.</ArticleTitle><Pagination><MedlinePgn>1-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/abt/tby011</ELocationID><Abstract><AbstractText><b>Background:</b> Shark new antigen receptor variable domain (V<sub>NAR</sub>) antibodies can bind restricted epitopes that may be inaccessible to conventional antibodies. <b>Methods:</b> Here, we developed a library construction method based on polymerase chain reaction (PCR)-Extension Assembly and Self-Ligation (named "EASeL") to construct a large V<sub>NAR</sub> antibody library with a size of 1.2 × 10<sup>10</sup> from six naïve adult nurse sharks (<i>Ginglymostoma cirratum</i>). <b>Results:</b> The next-generation sequencing analysis of 1.19 million full-length V<sub>NAR</sub>s revealed that this library is highly diversified because it covers all four classical V<sub>NAR</sub> types (Types I-IV) including 11% of classical Type I and 57% of classical Type II. About 30% of the total V<sub>NAR</sub>s could not be categorized as any of the classical types. The high variability of complementarity determining region (CDR) 3 length and cysteine numbers are important for the diversity of V<sub>NAR</sub>s. To validate the use of the shark V<sub>NAR</sub> library for antibody discovery, we isolated a panel of V<sub>NAR</sub> phage binders to cancer therapy-related antigens, including glypican-3, human epidermal growth factor receptor 2 (HER2), and programmed cell death-1 (PD1). Additionally, we identified binders to viral antigens that included the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) spike proteins. The isolated shark single-domain antibodies including Type I and Type II V<sub>NAR</sub>s were produced in <i>Escherichia coli</i> and validated for their antigen binding. A Type II V<sub>NAR</sub> (PE38-B6) has a high affinity (K<sub>d</sub> = 10.1 nM) for its antigen. <b>Conclusions:</b> The naïve nurse shark V<sub>NAR</sub> library is a useful source for isolating single-domain antibodies to a wide range of antigens. The EASeL method may be applicable to the construction of other large diversity gene expression libraries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Mingqian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Hejiao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiaolin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Tianyun</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Bryan D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flajnik</LastName><ForeName>Martin F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Maryland Baltimore School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Mitchell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antib Ther</MedlineTA><NlmUniqueID>101730822</NlmUniqueID><ISSNLinking>2516-4236</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">gene library construction</Keyword><Keyword MajorTopicYN="N">next-generation sequencing</Keyword><Keyword MajorTopicYN="N">phage display</Keyword><Keyword MajorTopicYN="N">shark VNAR</Keyword><Keyword MajorTopicYN="N">single-domain antibody</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>08</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30627698</ArticleId><ArticleId IdType="doi">10.1093/abt/tby011</ArticleId><ArticleId IdType="pii">tby011</ArticleId><ArticleId IdType="pmc">PMC6312525</ArticleId></ArticleIdList><pmc-dir>pmcsd</pmc-dir>
<ReferenceList><Reference><Citation>J Immunol Methods. 2006 Aug 31;315(1-2):171-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16962608</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9751746</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods Mol Biol. 2018;1701:147-167</Citation><ArticleIdList><ArticleId IdType="pubmed">29116504</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMC Biotechnol. 2007 Nov 19;7:78</Citation><ArticleIdList><ArticleId IdType="pubmed">18021450</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):E1083-91</Citation><ArticleIdList><ArticleId IdType="pubmed">23471984</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2005 Jan 7;280(1):607-17</Citation><ArticleIdList><ArticleId IdType="pubmed">15491997</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 2007 Mar 23;367(2):358-72</Citation><ArticleIdList><ArticleId IdType="pubmed">17258766</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Dev Comp Immunol. 2006;30(1-2):43-56</Citation><ArticleIdList><ArticleId IdType="pubmed">16146649</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Biochem. 2003 Sep;270(17):3543-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12919318</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Immunol. 2003 Sep;40(1):25-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12909128</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Immunol. 2005 Mar;35(3):936-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15688348</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Immunol. 2007 Jan;44(4):656-65</Citation><ArticleIdList><ArticleId IdType="pubmed">16500706</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2004 Jul 15;173(2):1129-39</Citation><ArticleIdList><ArticleId IdType="pubmed">15240702</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Investig Drugs. 2009 Nov;10(11):1212-24</Citation><ArticleIdList><ArticleId IdType="pubmed">19876789</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell. 2012 Mar 16;148(6):1081-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22424219</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Toxicol Pathol. 1999 Sep-Oct;27(5):536-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10528633</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 2010 Jul 9;400(2):155-70</Citation><ArticleIdList><ArticleId IdType="pubmed">20450918</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 2001 Feb 1;248(1-2):31-45</Citation><ArticleIdList><ArticleId IdType="pubmed">11223067</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Exp Med Biol. 2009;655:49-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20047035</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hepatology. 2014 Aug;60(2):576-87</Citation><ArticleIdList><ArticleId IdType="pubmed">24492943</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods Mol Biol. 2012;907:85-107</Citation><ArticleIdList><ArticleId IdType="pubmed">22907347</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Immunol. 2001 Aug;38(4):313-26</Citation><ArticleIdList><ArticleId IdType="pubmed">11566324</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MAbs. 2015;7(1):15-25</Citation><ArticleIdList><ArticleId IdType="pubmed">25523873</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2004 Sep 17;305(5691):1770-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15319492</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MAbs. 2012 Sep-Oct;4(5):592-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22820551</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Cancer Ther. 2013 Jan;12(1):48-57</Citation><ArticleIdList><ArticleId IdType="pubmed">23136186</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antib Ther. 2018 Jun;1(1):1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">30101214</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1846-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16446445</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Immunol. 2007 Mar;44(7):1775-83</Citation><ArticleIdList><ArticleId IdType="pubmed">17007931</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E733-E742</Citation><ArticleIdList><ArticleId IdType="pubmed">29311317</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMC Immunol. 2004 May 06;5:8</Citation><ArticleIdList><ArticleId IdType="pubmed">15132758</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Med Microbiol Immunol. 2009 Aug;198(3):157-74</Citation><ArticleIdList><ArticleId IdType="pubmed">19529959</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioinformatics. 2011 Nov 1;27(21):2957-63</Citation><ArticleIdList><ArticleId IdType="pubmed">21903629</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Cancer Ther. 2015 Dec;14(12):2789-96</Citation><ArticleIdList><ArticleId IdType="pubmed">26443804</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8155-60</Citation><ArticleIdList><ArticleId IdType="pubmed">24830426</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>EBioMedicine. 2016 Jun;8:40-48</Citation><ArticleIdList><ArticleId IdType="pubmed">27428417</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Pharmacol. 2008 Oct;8(5):609-15</Citation><ArticleIdList><ArticleId IdType="pubmed">18619558</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods Mol Biol. 2018;1827:109-127</Citation><ArticleIdList><ArticleId IdType="pubmed">30196494</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods Mol Biol. 2009;525:293-308, xiv</Citation><ArticleIdList><ArticleId IdType="pubmed">19252855</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2015 Mar 11;6:6536</Citation><ArticleIdList><ArticleId IdType="pubmed">25758784</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proteins. 2004 Apr 1;55(1):187-97</Citation><ArticleIdList><ArticleId IdType="pubmed">14997552</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Exp Med. 1970 Aug 1;132(2):211-50</Citation><ArticleIdList><ArticleId IdType="pubmed">5508247</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunogenetics. 2002 Oct;54(7):501-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12389098</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Methods. 2009 May;6(5):343-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19363495</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2016 Sep 02;11(9):e0161801</Citation><ArticleIdList><ArticleId IdType="pubmed">27588755</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Feng, Mingqian" sort="Feng, Mingqian" uniqKey="Feng M" first="Mingqian" last="Feng">Mingqian Feng</name></region><name sortKey="Bian, Hejiao" sort="Bian, Hejiao" uniqKey="Bian H" first="Hejiao" last="Bian">Hejiao Bian</name><name sortKey="Flajnik, Martin F" sort="Flajnik, Martin F" uniqKey="Flajnik M" first="Martin F" last="Flajnik">Martin F. Flajnik</name><name sortKey="Fleming, Bryan D" sort="Fleming, Bryan D" uniqKey="Fleming B" first="Bryan D" last="Fleming">Bryan D. Fleming</name><name sortKey="Fu, Tianyun" sort="Fu, Tianyun" uniqKey="Fu T" first="Tianyun" last="Fu">Tianyun Fu</name><name sortKey="Fu, Ying" sort="Fu, Ying" uniqKey="Fu Y" first="Ying" last="Fu">Ying Fu</name><name sortKey="Ho, Mitchell" sort="Ho, Mitchell" uniqKey="Ho M" first="Mitchell" last="Ho">Mitchell Ho</name><name sortKey="Hong, Jessica" sort="Hong, Jessica" uniqKey="Hong J" first="Jessica" last="Hong">Jessica Hong</name><name sortKey="Wu, Xiaolin" sort="Wu, Xiaolin" uniqKey="Wu X" first="Xiaolin" last="Wu">Xiaolin Wu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000627 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000627 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:30627698
|texte= Construction and next-generation sequencing analysis of a large phage-displayed VNAR single-domain antibody library from six naïve nurse sharks.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:30627698" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |